Literature DB >> 28007581

Different doses of dexmedetomidine reduce plasma cytokine production, brain oxidative injury, PARP and caspase expression levels but increase liver oxidative toxicity in cerebral ischemia-induced rats.

Orhan Akpınar1, Mustafa Nazıroğlu2, Hatice Akpınar3.   

Abstract

Cerebral ischemia-induced progression of brain, liver, and erythrocyte oxidative injuries might be modulated by dexmedetomidine (DEX) as a potent antioxidant and anti-inflammatory drug. The present study was conducted to explore whether two different doses of DEX protect against plasma cytokine and brain, liver and erythrocyte oxidative toxicity and apoptosis in cerebral ischemia-induced rats. Forty-two rats were equally divided into 7 groups. The first and second groups were used as untreated and sham controls, respectively. The third (DEX4) and fourth (DEX40) groups received 4mg/kg and 40mg/kg DEX treatments. The fifth, sixth and seventh group were operated on to induce cerebral ischemia. The fifth, sixth and seventh groups are used to represent cerebral ischemia, cerebral ischemia+DEX4, and cerebral ischemia+DEX40, respectively. DEX was intraperitoneally given to the DEX groups at the 3rd, 24th and 48th hour. Brain and erythrocyte lipid peroxidation (MDA) levels and plasma IL-1β and TNF-α levels were high in the cerebral ischemia group although they were low in the DEX4 and DEX40 groups. Decreased glutathione peroxidase (GSH-Px) and reduced glutathione (GSH) values in the brain and erythrocyte of the cerebral ischemia group were increased by the DEX treatments, although PARP, and the caspase 3 and 9 expressions in the brain were further decreased. Conversely, the cerebral ischemia-induced decrease in the liver vitamin A, vitamin E, GSH, and GSH-Px were further decreased by the DEX treatments, although MDA level, PARP, and caspase 3 and 9 expressions were further increased by the DEX treatments. In conclusion, DEX induced protective effects against cerebral ischemia-induced brain and erythrocyte oxidative injuries through regulation of the antioxidant level and cytokine production. However, both doses of DEX induced oxidative toxicity and apoptotic effects in the rats' livers.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brain; Cerebral ischemia; Cytokine; Dexmedetomidine; Liver; Oxidative stress

Mesh:

Substances:

Year:  2016        PMID: 28007581     DOI: 10.1016/j.brainresbull.2016.12.005

Source DB:  PubMed          Journal:  Brain Res Bull        ISSN: 0361-9230            Impact factor:   4.077


  5 in total

1.  Dexmedetomidine Promotes SH-SY5Y Cell Resistance Against Impairment of Iron Overload by Inhibiting NF-κB Pathways.

Authors:  Xi-Bei Hu; Zhi-Yu Xi; Lin-Qing Liu; Kai Kang; Wan-Hong Li; Yu-Xian Shen; Fang Kang; Juan Li
Journal:  Neurochem Res       Date:  2019-01-29       Impact factor: 3.996

2.  Tailored Therapeutic Doses of Dexmedetomidine in Evolving Neuroinflammation after Traumatic Brain Injury.

Authors:  Dicle Karakaya; Canan Cakir-Aktas; Sennur Uzun; Figen Soylemezoglu; Melike Mut
Journal:  Neurocrit Care       Date:  2021-11-16       Impact factor: 3.210

3.  Chemo brain or tumor brain - that is the question: the presence of extracranial tumors profoundly affects molecular processes in the prefrontal cortex of TumorGraft mice.

Authors:  Anna Kovalchuk; Yaroslav Ilnytskyy; Rocio Rodriguez-Juarez; Svitlana Shpyleva; Stepan Melnyk; Igor Pogribny; Amanda Katz; David Sidransky; Olga Kovalchuk; Bryan Kolb
Journal:  Aging (Albany NY)       Date:  2017-07-29       Impact factor: 5.682

4.  Dexmedetomidine pretreatment alleviates cerebral ischemia/reperfusion injury by inhibiting neuroinflammation through the JAK2/STAT3 pathway.

Authors:  Huan Liu; Jianli Li; Li Jiang; Jinhua He; Huanhuan Zhang; Keyan Wang
Journal:  Braz J Med Biol Res       Date:  2022-07-13       Impact factor: 2.904

5.  SOD2 Mediates Curcumin-Induced Protection against Oxygen-Glucose Deprivation/Reoxygenation Injury in HT22 Cells.

Authors:  Yuqing Wang; Yuanyuan Zhang; Liang Yang; Jin Yuan; Ji Jia; Shuai Yang
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-29       Impact factor: 2.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.